Abstract:In general, iron represents a double-edged sword in metabolism in most tissues, especially in the brain. Although the high metabolic demands of brain cells require iron as a redox-active metal for ATP-producing enzymes, the brain is highly vulnerable to the devastating consequences of excessive iron-induced oxidative stress and, as recently found, to ferroptosis as well. The blood-brain barrier (BBB) protects the brain from fluctuations in systemic iron. Under pathological conditions, especially in acute brain pathologies such as stroke, the BBB is disrupted, and iron pools from the blood gain sudden access to the brain parenchyma, which is crucial in mediating stroke-induced neurodegeneration. Each brain cell type reacts with changes in their expression of proteins involved in iron uptake, efflux, storage, and mobilization to preserve its internal iron homeostasis, with specific organelles such as mitochondria showing specialized responses. However, during ischemia, neurons are challenged with excess extracellular glutamate in the presence of high levels of extracellular iron; this causes glutamate receptor overactivation that boosts neuronal iron uptake and a subsequent overproduction of membrane peroxides. This glutamate-driven neuronal death can be attenuated by iron-chelating compounds or free radical scavenger molecules. Moreover, vascular wall rupture in hemorrhagic stroke results in the accumulation and lysis of iron-rich red blood cells at the brain parenchyma and the subsequent presence of hemoglobin and heme iron at the extracellular milieu, thereby contributing to iron-induced lipid peroxidation and cell death. This review summarizes recent progresses made in understanding the ferroptosis component underlying both ischemic and hemorrhagic stroke subtypes.

Rationale and Current Evidence for Testing Iron Chelators for Treating Stroke

Iron Chelators for Acute Stroke.

Iron Enhances The Neurotoxicity Of Amyloid Beta

Iron, Ferroptosis, and Ischemic Stroke

Therapeutic applications of chelating drugs in iron metabolic disorders of the brain and retina

Iron Neurotoxicity and Protection by Deferoxamine in Intracerebral Hemorrhage

The role of metal ions in stroke: Current evidence and future perspectives

Iron As A Therapeutic Target In Intracerebral Hemorrhage: Preclinical Testing Of Deferoxamine

Novel Chelators for Central Nervous System Disorders That Involve Alterations in the Metabolism of Iron and Other Metal Ions

Deciphering the Iron Side of Stroke: Neurodegeneration at the Crossroads Between Iron Dyshomeostasis, Excitotoxicity, and Ferroptosis

The Damage Mechanisms of Iron Ion in Intracerebral Hemorrhage and the Neuroprotective Effects of Iron Chelator

Brain Iron Metabolism, Redox Balance and Neurological Diseases

Iron toxicity in intracerebral hemorrhage: Physiopathological and therapeutic implications

Neurodegenerative diseases and therapeutic strategies using iron chelators

New Perspectives in Iron Chelation Therapy for the Treatment of Neurodegenerative Diseases

Iron Enhances the Neurotoxicity of Amyloid β

Iron homeostasis imbalance and ferroptosis in brain diseases

Iron toxicity, lipid peroxidation and ferroptosis after intracerebral haemorrhage

Neuroprotective multifunctional iron chelators: from redox-sensitive process to novel therapeutic opportunities

Advances in iron chelation: an update

Iron and Intracerebral Hemorrhage: From Mechanism to Translation